Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia

Leukemia

Volumn 13, Issue 12, 1999, Pages 1901-1928

  Van Dongen, J J M ^a,k   Macintyre, E A ^b   Gabert, J A ^c   Delabesse, E ^b   Rossi, V ^d   Saglio, G ^e   Gottardi, E ^e   Rambaldi, A ^f   Dotti, G ^f   Griesinger, F ^g   Parreira, A ^h   Gameiro, P ^h   Diáz, M González ⁱ   Malec, M ^j   Langerak, A W ^a   San Miguel, J F ⁱ   Biondi, A ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d SAN GERARDO HOSPITAL   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PRIMER DNA;

ACUTE LEUKEMIA; CELL LINE; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 4; CHROMOSOME TRANSLOCATION 8; CHROMOSOME TRANSLOCATION 9; EDITORIAL; FLOW CYTOMETRY; FUSION GENE; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STANDARDIZATION; TECHNIQUE;

EID: 0032757710     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401592     Document Type: Editorial

References (196)

1. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, González M, Caballero D, Garcia-Marcos MA, Ramos F, Fernandez-Calvo J, Calmuntia MJ, Diaz-Mediavilla J, Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470.
2. Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Cole Sinclair MF, Chim JS, Cannell P, Secker-Walker LM, Mehta AB, Prentice HG, Hoffbrand AV. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997; 11: 1732-1741.
3. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco FL. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. GIMEMA-AIEOP Multicenter 'AIDA' Trial. Blood 1998; 92: 784-789.
4. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui C-H, Campana D. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-554.
5. Cavé H, Van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New Engl J Med 1998; 339: 591-598.
6. Van Dongen JJM, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, Van Wering ER, Ludwig W-D, Basso G, De Bruijn MAC, Cazzaniga G, Hettinger K, Van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram CR. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
7. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-1434.
8. Van Dongen JJM, Szczepański T, de Bruijn MAC, Van den Beemd MWM, De Bruin-Versteeg S, Wijkhuijs JM, Tibbe GJM, Van Gastel-Mol EJ, Groeneveld K, Hooijkaas H. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996; 2: 121-133.
9. San Miguel JF, Van Dongen JJM, Bartram CR, Parreira A, Wörmann B, Biondi A, Porwit MacDonald A. Investigation of minimal residual disease (MRD) in acute leukemia (AL): international standardization and evaluation. In: SS Baig (ed.). Cancer Research Supported under BIOMED-1. Biomedical and Health Research. IOS Press: Amsterdam, 1998; 24: 300-306.
10. Pongers-Willemse MJ, Seriu T, Stolz F, D'Aniello E, Gameiro P, Pisa P, González M, Bartram CR, Panzer-Grümayer ER, Biondi A, San Miguel JF, Van Dongen JJM. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118.
11. Lúcio P, Parreira A, Van den Beemd MWM, Van Lochem EG, Van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Van Dongen JJM, San Miguel JF. Flow cytometric analysis of normal B-cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999; 13: 419-427.
12. De Klein A, Geurts van Kessel A, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N. Groffen J, Stephenson JR. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765-767.
13. Hermans A, Heisterkamp N, Von Lindern M, Van Baal S, Meijer D, Van der Plas D, Wiedemann LM, Groffen J, Bootsma D, Grosveld G. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33-40.
14. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-149.
15. Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Mugneret F, Moorman AV, Secker-Walker LM. Ten novel 11q23 chromosomal partner sites. Leukemia 1998; 12: 811-822.
16. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Catovsky D, Silva ML, Dyer MJ. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998; 91: 1873-1881.
17. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.
18. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151-1168.
19. Pui CH, Evans WE. Acute lymphoblasic leukemia. New Engl J Med 1998; 339: 605-615.
20. Biondi A, Rambaldi A. Molecular diagnosis and monitoring of acute myeloid leukemia. Leukemia Res 1996; 20: 801-807.
21. Rubnitz JE, Behm FG, Pui CH, Evans WE, Relling MV, Raimondi SC, Harrison PL, Sandlund JT, Ribeiro RC, Grosveld G, Downing IR. Genetic studies of childhood acute lymphoblaslic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia 1997; 11: 1201-1206.
22. Martinez-Climent JA. Molecular cytogenetics of childhood hematological malignancies. Leukemia 1997; 11: 1999-2021.
23. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, Koeffler HP, Takeuchi S, Janssen JWG, Seriu T, Bartram CR, Sallan SE, Gilliland DG, Golub RT. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252-4258.
24. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M. Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Blood 1997; 90: 571-577.
25. Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD, Cleary ML. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 1990; 60: 535-545.
26. Kamps MP, Murre C, Sun XH, Baltimore D. A new homeobox gene contributes the binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 1990; 60: 547-555.
27. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM, Canaani E. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992; 71: 701-708.
28. Morrissey J, Tkachuk DC, Milatovich A, Francke U, Link M, Cleary ML. A serine/proline-rich protein is fused to HRX in t(4;11) acute leukemias. Blood 1993; 81: 1124-1131.
29. Domer PH, Fakharzadeh SS, Chen C-S, Jockel J, Johansen L, Silverman GA, Kersey JH, Korsmeyer SJ. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci USA 1993; 90: 7884-7888.
30. Erickson P, Gao J, Chang K-S, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rovvley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation series, runt. Blood 1992; 80: 1825-1831.
31. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1/MTG-8 fusion transcript. EMBO J 1993; 12: 2715-2721.
32. Heisterkamp N, Stephenson JR, Groffen J, Hansen P, De Klein A, Bartram CR, Grosveld G. Localization of the c-ABL oncogene adjacent to a translocalion breakpoint in chonic myelocytic leukemia. Nature 1985; 306: 239-242.
33. Golub TR, Barker FG, Bohlander SK, Heibert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley J, Gilliland DG. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917-4921.
34. Romana SP, Mauchauffé M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA. The t(12;21) of acute lymphoblastic leukemia results in a TEL-AML1 gene fusion. Blood 1995; 85: 3662-3670.
35. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitrowsky ER, Evans RM. Chromosomal translocation t(15:17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
36. De Thé H, Lavau C, Marchio A, Chomienne S, Degos L, Dejean A. The PML-RARα fusion mRNA generated by the t(15:17) translocation in promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66; 675-684.
37. Liu PP, Tarlé SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS. Fusion between tratiscription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041-1044.
38. Bernard O, Lecointe N, Jonveaux P, Souyri M, Mauchauffé M, Berger R, Larsen CJ, Mathieu-Mahul D. Two site-specific deletions and t(1;14) translocation restricted to human T-cell acute leukemias disrupt the 5′ part of the tal-1 gene. Oncogene 1991; 6: 1477-1488.
39. Breit TM, Mol EJ, Wolvers-Tettero ILM, Ludwig W-D, Van Wering ER, Van Dongen JJM. Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T-cell receptor αβ lineage: T-cell receptor δ gene deletion mechanism affects multiple genes. J Exp Mol 1993; 177: 965-977.
40. Drexler HG, McLeod RAF, Borkhardt A, Janssen JWG. Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines. Leukemia 1995; 9: 480-500.
41. Carroll AJ, Crist WM, Parmley RT, Roper M, Cooper MD, Finley WH. Pre-B cell leukemia associated with chromosome translocation 1:19. Blood 1984; 63: 721-724.
42. Michael PM, Levin MD, Garson OM. Translocation 1;19 - a new cytogenetic abnormality in acute lymphocytic leukemia. Cancer Genet Cytogenet 1984; 12: 333-341.
43. Williams DL, Look AT, Melvin SL, Robertson PK, Dahl G, Flake T, Stass S. New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemia. Cell 1984; 36: 101-109.
44. Crist WM, Carrol AJ, Shuster JJ, Behm FG, Whitehead M, Vieti TJ. Look AT, Mahoney D, Ragab A, Pullen DJ, Land VJ. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the 1(1;19)(q23;p13). A pediatric Oncology Group Study. Blood 1990; 76: 117-122.
45. Raimondi SC, Behm FG, Robertson PK, Williams DL, Pui C-H, Crist WM, Look AT, Rivera GK. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implication of the t(1;19). J Clin Oncol 1990; 8: 1380-1388.
46. Rambaldi A, Attuati V, Bassan R, Neonato MG, Viero P, Battista R, Di Bona E, Rossi G, Pogliani E, Ruggeri M, Amaru R, Rivolta A, Giudici G, Biondi A, Barbui T. Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblaslic leukemia. Leuk Lymphoma 1996; 21: 457-466.
47. Groupe Francais de Citogenetique Hematologique: cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlation with hematologic findings and outcome. A collaborative study of the Groupe Francais de Citogenetique Hematologique. Blood 1996; 87: 3135-3142.
48. Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen J, Steuber CP, Cleary ML. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implication for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group Study. Blood 1993; 83: 1086-1091.
49. Mellentin JD, Nourse J, Hunger SP, Smith SD, Cleary ML. Molecular analysis of the t(1;19) breakpoint cluster region in pre-B-cell ALL. Gene Chromosom Cancer 1990; 2: 239-247.
50. Izraeli S, Kovar H, Gadner H, Lion T. Unexpected heterogeneity in E2A/PBX1 fusion messenger RNA detected by the polymerase chain reaction in pediatric patients with acute lymphoblastic leukemia. Blood 1992; 80: 1413-1417.
51. Privitera F, Luciano A, Ronchetti D, Arico M, Santostasi T, Basso G, Biondi A. Molecular variants of the 1;19 chromosomal translocation in pediatric acute lymphoblastic leukemia (ALL). Leukemia 1994; 8: 554-559.
52. Troussard X, Rimokh R, Valensi F, Leboeuf D, Fenneteau O, Guitard A-M, Manel A-M, Schillenger F, Leglise C, Brizard A, Gardais J, Lessard M, Flandrin G, MacIntyre E. Heterogeneity of t(1;19)(q23;p13) acute leukemias. Br J Haematol 1995; 89: 516-526.
53. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762-769.
54. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, Löffler H, Hossfeld D, Heil G, Handt S, Heyll A, Diedrich H, Fischer K, Weiss A, Völkers B, Aydemir Z, Fonatsch C, Gökbuget N, Thiel E, Hoelzer D. Immunophenotypic and genotypic features, clinical characteristics and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
55. Hagemeijer A, Van Dongen JJM, Slater RM, Van 't Veer MB, Behrendt H, Hählen K, Sizoo W, Abels J. Characterization of the blast cells in acute leukemia with translocation (4;11): report of eight additional cases and of one case with a variant translocation. Leukemia 1987; 1: 24-31.
56. Borowitz MJ, Shuster J, Land V, Steuber C, Pullen D, Vietti T. Myeloid antigen expression in childhood acute lymphoblastic leukemia. New Engl J Med 1991; 325: 1378-1382.
57. Griesinger F, Elfers H, Ludwig WD, Falk M, Rieder H, Harbott J, Lampert F, Heinze B, Hoelzer D, Thiel E, Riehm H, Wörmann B, Fonatsch C, Hiddemann W. Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11). Leukemia 1994; 8: 542-548.
58. Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19) (q23;p13) and MLL gene rearrangements. Blood 1996; 87: 1134-1139.
59. Nilson I, Löchner K, Siegler G, Greil J, Beck JD, Fey GH, Marschalek R. Exon/intron structure of the human ALL-1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukemias. Br J Haematol 1996; 93: 966-972.
60. Blutters-Sawatzki R, Borkhardt A, Grathwohl J, Repp R, Rheinisch-Becker I, Bohle RM, Lampert F. Secondary acute myeloid leukemia with translocation (4;11) and MLL/AF4 rearrangement in a 15-year-old boy treated for common acute lymphoblastic leukemia 11 years earlier. Ann Hematol 1995; 70: 31-35.
61. Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S, Secker-Walker LM. Hematologic malignancies with t(4:11)(q21;q23): a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop. Leukemia 1998; 12: 779-787.
62. Martineau M, Berger R, Lillington DM, Moorman AV, Secker-Walker LM. The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. EU Concerted Action 11q23 Workshop. Leukemia 1998; 12: 788-791.
63. Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM. Hematological malignancies with t(9;11)(p21-22;q23): a laboratory and clinical study of 125 cases. European 11q23 Workshop. Leukemia 1998; 12: 792-800.
64. Lillington DM, Young BD, Berger R, Martineau M, Moorman AV, Secker-Walker LM. The t(10;11)(p12;q23) translocation in acute leukaemia: a cytogenetic and clinical study of 20 patients. European 11q23 Workshop. Leukemia 1998; 12: 801-804.
65. Moorman AV, Hagemeijer A, Charrin C, Rieder H, Secker-Walker LM. The translocations, t(11;19)(q23;p13.1) and t(11;19) (q23;p13.3): a cytogenetic and clinical profile of 53 patients. European 11q23 Workshop. Leukemia 1998; 12: 805-810.
66. Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia 1998; 12: 840-844.
67. Löchner K, Siegler G, Führer M, Greil J, Beck JD, Fey GH, Marschalek R. A specific deletion in the breakpoint cluster region of the ALL-1 gene is associated with acute lymphoblastic T-cell leukemias. Cancer Res 1996; 56: 2171-2177.
68. Schichman SA, Caligiuri MA, Gu Y, Strout MP, Canaani E, Bloomfield CD, Croce CM. ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci USA 1994; 91: 6236-6239.
69. Schnittger S, Wormann B, Hiddemann W, Griesinger F. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood 1998; 92: 1728-1734.
70. Nilson I, Reichel M, Ennas MG, Greim R, Knorr C, Siegler G, Greil J, Fey GH, Marschalek R. Exon/intron structure of the human AF-4 gene, a member of the AF-4/LAF-4/FMR-2 gene family coding for a nuclear protein with structural alterations in acute leukemia. Br J Haematol 1997; 98: 157-169.
71. Felix CA, Hosler MR, Slater DJ, Parker RI, Masterson M, Whitlock JA, Rebbeck TR, Nowell PC, Lange BJ. MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in childeren. J Pediatr Hematol Oncol 1998; 20: 299-308.
72. Chen C-S, Sorensen PH, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA, Hammond GD, Kersey JH. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-2393.
73. Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, Pullen DJ, Cleary ML. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia, a Pediatric Oncology Group study. Blood 1994; 84: 570-573.
74. Biondi A, Rambaldi A, Rossi V, Elia L, Caslini C, Basso G, Battista R, Barbui T, Mandelli F, Masera G, Croce C, Canaani E, Cimino G. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood 1993; 82: 2943-2947.
75. Cimino G, Elia L, Rivolta A, Rapanotti MC, Rossi V, Alimena G, Annino L, Canaani E, Lo Coco F, Biondi A. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. Br J Haematol 1996; 92: 659-664.
76. Rowley JD. Identification of a translocation with quinicrine fluorescence in a patient with acute leukemia. Ann Genet 1973; 16: 109-112.
77. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031-2036.
78. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86: 1-14.
79. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-330.
80. Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, Nagase T, Yokoyama Y, Ohki M. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 1998; 91: 4028-4037.
81. Xue Y, Yu F, Xin Y, Lu D, Zou Z, Guo Y, Xie X. t(8;20)(q22;p13): a novel variant translocation of t(8;21) in acute myeloblastic leukaemia. Br J Haematol 1997; 98: 733-735.
82. Roulston D, Espinosa Rr, Nucifora G, Larson RA, Le Beau MM, Rowley JD. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood 1998; 92: 2879-2885.
83. Andrieu V, Radford-Weiss I, Troussard X, Chane C, Valensi F, Guesnu M, Haddad E, Viguier F, Dreyfus F, Varet B, Flandrin G, Macintyre E. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol 1996; 92: 855-865.
84. Mitterbauer M, Kusec R, Schwarzinger I, Haas OA, Lechner K, Jaeger U. Comparison of karyotype analysis and RT-PCR for AML1/ETO in 204 unselected patients with AML. Ann Hematol 1998; 76: 139-143.
85. Van de Locht LT, Smetsers TF, Wittebol S, Raymakers RA, Mensink EJ. Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia. Leukemia 1994; 8: 1780-1784.
86. Tighe JE, Calabi F. Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2. Blood 1994; 84: 2115-2121.
87. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997; 24: 17-31.
88. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-4179.
89. Stanulla M, Wang J, Chervinsky DS, Aplan PD. Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus. Leukemia 1997; 11: 490-496.
90. Langabeer SE, Walker H, Rogers JR, Burnett AK, Wheatley K, Swirsky D, Goldstone AH, Linch DC. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC: Adult Leukaemia Working Party. Br J Haematol 1997: 99: 925-928.
91. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, Block AM, Knuutila S, Herzig GP, Bloomfield CD. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996; 88: 2183-2191.
92. Elmaagacli AH, Beelen DW, Stockova I, Trzensky S, Kroll M, Schaefer UW, Stein C, Opalka B. Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation. Blood 1997; 90: 3230-3231.
93. Preudhomme C, Philippe N, Macintyre E, Henic N, Lai JL, Jouet JP, Cosson A, Fenaux P. Persistence of AML1/ETO fusion mRNA in t(8;21) acute myeloid leukemia (AML) in prolonged remission: is there a consensus? Leukemia 1996; 10: 186-188.
94. Rowley JD. A novel consistent chromosome abnormality in chronic myelogenous leukemia detected by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
95. Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgstrom GH, Brandt L, Catovsky D, de la Chapelle A, Dewald GW, Garson OM, Garwicz S, Golomb HM, Hossfeld DK, Lawler SD, Mitelman F, Nilsson P, Pierre RV, Philip P, Prigogina E, Rowley JD, Sakurai M, Sandberg AA, Secker-Walker LM, Tricot C, Van Den Berghe H, Van Orshoven A, Vuopio P, Whang-Peng J. Chromosomal abnormalities identity high-risk and low-risk patients with acute lymphoblaslic leukemia. Blood 1986; 67: 415-420.
96. Maurer J, Jansen JW, Thiel E, Van Denderen J, Ludwig WD. Aydemir U, Heinze B, Fonatsch C, Harboll J, Reiter A, Riehm H, Hoelzer D, Bartram CR. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerrase chain reaction. Lancet 1991; 337: 1055-1058.
97. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319: 990-998.
98. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 95-99.
99. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550-554.
100. Clark S, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987; 235: 85-88.
101. Selleri L, von Linderen M, Hermans A, Meijer D, Torelli G, Grosveld G. Chronic myeloid leukemia may be associated with several bcr/abl transcripts including the acute lymphoid leukemia-type 7 kb transcript. Blood 1990; 75: 1146-1153.
102. Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, De Micheli D. Parziale A, Fornaci MN, Martinelli G, Salvatore F. Consistent amounts of acute leukemia-associated P190 bcr/abl transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 1996; 87: 1075-1080.
103. Van Rhee F, Hochhaus A, Lin F, Melo V, Goldman JM, Cross NC. p190 BCR/ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996; 87: 5213-5217.
104. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991; 5: 196-199.
105. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer C, Bloomfield CD. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a cancer and leukemia group B study (8762). Blood 1992; 12 2983-2990.
106. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91: 3995-4019.
107. Sierra J, Radlich J, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J. Bryant E, Nash RA, Sanders JE, Storb R, Sullivan KM, Appelbaum FR, Anasetti C. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997; 90: 1410-1414.
108. Dunlop LC, Powles R, Singhai S, Treleaven JG, Swansbury GJ, Meller S, Pinkerton CR, Norton C, Metha J. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996; 17: 365-369.
109. Preudhomme C, Henic N, Cazin B, Lai JL, Bertheas MF, Vanrumbeke M, Lemoine F, Jouet JP, Deconninck E, Nelken B, Cosson A, Fenaux P. Good correlation between RT-PCR analysts and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia 1997; 11: 294-298.
110. Radich JP, Gehly G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kessler P, Kirk J, Ladne P, Thomas ED, Appelbaum FA. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89: 2602-2609.
111. Verfaillie CM. Chronic myelogenous leukemia: too much or too little growth, or both? Leukemia 1998; 12: 136-138.
112. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
113. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J. Incidence and clinical outcome of childeren with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996; 10: 957-963.
114. Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood 1987; 70: 1584-1588.
115. Najfeld V, Celler M, Troy K, Scalise A. Acquisition of the Ph chromosome and BCR-ABL fusion product in AML-M2 and t(8;21) leukemia: cytogenetic and FISH evidence for a late event. Leukemia 1998; 12: 517-519.
116. Paietta E, Racevskis J, Bennett JM, Neuberg D, Cassileth PA, Rowe JM, Wiernik PH. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 1998; 12: 1881-1885.
117. Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R, Kirk J, Lee A, Kessler P, Appelbaum F, Gehly G. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 1994; 8: 1688-1695.
118. Paietta E, Racevskis J, Neuberg D, Rowe JM, Goldstone AH, Wiernik PH. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia 1997; 11: 1887-1890.
119. Chissoe SL, Bodenteich A, Wang YF, Wang YP, Burian D, Clifton SW, Crabtree J, Freeman A, Iyer K, Jian L, Ma Y, McLaury HJ, Pan HQ, Sarhan OH, Toth S, Wang Z, Zhang G, Heisterkamp N, Groffen J, Roe BA. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 1995; 27: 67-82.
120. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89: 546-554.
121. Melo JV, Hochhaus A, Yan XH, Goldman JM. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol 1996; 92: 684-686.
122. Melo JV, Myint H, Galton DAG, Goldman JM. P190 BCR/ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia? Leukemia 1994; 8: 208-211.
123. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) (published erratum: Blood 1997: 89: 4244). Blood 1996; 88: 2410-2414.
124. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) (published erratum: Blood 1997: 89: 4244). Blood 1996; 88: 2410-2414.
125. Costello R, Lafage MYTVB, Sainty D, Arnoulet C, Mozziconacci MJ, Bouabdallah R, Gastaut JA, Maraninchi D, Gabert J. Philadelphia chromosome-negative chronic myeloid leukaemia: a report of 14 new cases. Br J Haematol 1995; 90: 346-352.
126. San Miguel JF, González M, Orfao A. Detection of minimal residual disease in myeloid malignancies. In: Degos L, Linch DC, Löwenberg B (eds). Text Book of Malignant Haematology. Martin Dunitz: London, 1999, pp 871-891.
127. Gabert J, Thuret I, Lafage M, Carcassonne Y, Maraninchi D, Mannoni P. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone-marrow transplantation. Lancet 1989; 2: 1125-1128.
128. Pichert G, Roy DC, Gonin R, Alyea EP, Belanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C, Soiffer RJ, Ritz J. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1995; 13: 1704-1713.
129. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632-2638.
130. Costello R, Kirk J, Gabert J. Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leuk Lymphoma 1996; 20: 239-243.
131. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275-276.
132. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Quantification of residual disease in chronic myelogenous leukemia patients on interteron-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
133. Sawyers CL. Chronic myeloid leukemia. New Engl J Med 1999; 340: 1330-1340.
134. Mensink E, Van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.
135. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan GC, Pui CH, Grosveld G, Downing JR. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-1989.
136. Cayuela JM, Baruchel A, Orange C, Madani A, Auclere MF, Daniel MT, Schaison G, Sigaux F. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 1996; 88: 302-308.
137. Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroux C, Guo C, Vilmer E, Marynen P, Grandchamp B. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996; 87: 2891-2899.
138. Cavé H, Cacheux V, Raynaud S, Brunie G, Bakkus M, Cochaux P, Preudhomme C, Lai JL, Vilmer E, Grandchamp B. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. Leukemia 1997; 11: 1459-1464.
139. Raynaud S, Mauvieux L, Cayuela J, Bastard C, Bilhou-Nabera C, Debuire B, Bories D, Boucheix C, Charrin C, Fière D, Gabert J. TEL/AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia. Leukemia 1996; 10: 1529-1530.
140. Maloney KW, Rubnitz JE, Cleary ML. Frankel LS, Hakami N, Link MP, Pullen DJ, Hunger SP. Lack of ETV6 (TEL) gene rearrangements or p16INK4A/p15INK4B homozygous gene deletions in infant acute lymphoblastic leukemia. Leukemia 1997; 11: 979-983.
141. Loh ML, Silverman LB, Young ML, Neuberg D, Golub TR, Sallan SE, Gilliland DG. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998: 92: 4792-4797.
142. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997: 90: 4933-4937.
143. Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, Ritter J, Schwabe D, Harms D, Schrappe M, Henze G. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 1998: 91: 1716-1722.
144. Zuna J, Hrusak O, Kalinova M, Muzikova K, Stary J, Trka J. TEL/AML1 positivity in childhood ALL: average or better prognosis? Czech Paediatric Haematology Working Group. Leukemia 1999; 13: 22-24.
145. Golub TR, Barker GF, Lovett M, Gilliland DC. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
146. Lo Coco F, Pisegna S, Diverio D. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 1997; 82: 364-370.
147. Baens M, Peeters P, Gau C, Aerssens J, Marynen P. Genomic organization of TEL: the human ETS-variant gene 6. Genome Res 1996; 6: 404-413.
148. Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, Yokoyama K, Soeda E, Ohki M. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res 1995; 23: 2762-2769.
149. Rowely JD, Golomb HM, Doughery C.15/17 Translocation: a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1977; i: 549-550.
150. Longo L, Pandolfi PP, Biondi A, Rambaldi A, Mencarelli A, Lo Coco F, Diverio D, Pegoraro L, Avanzi G, Tabilio A, Donti E, Grignani F, Pelicci PG. Rearrangements and aberrant expression of the RARa gene in acute promyelocytic leukemias. J Exp Med 1990; 172: 1571-1575.
151. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577-1580.
152. De Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990; 347: 558-561.
153. Lemons RS, Eilander D, Waldmann RA, Rebentisch M, Frej AK, Ledbetter DM, Willmann C, McConnell T, O'Connel P. Cloning and characterization of the t(15;17) translocation breakpoint region in acute promyelocytic leukemia. Genes Chromosom Cancer 1990; 2: 79-87.
154. Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 440-450.
155. Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogenic retinoic acid. Nature 1987; 330: 624-629.
156. Biondi A, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay M, Lo Coco F, Diverio D, Pagliani EM, Lanzi EM, Madelli F, Masera G, Barbui T, Pelicci PG. Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia in polymerase chain reaction. Blood 1992; 80: 492-497.
157. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25.
158. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999: 94: 12-22.
159. Yanagisawa K, Horiuchi T, Fujila S. Establishment and characterization of a new human leukemia cell line derived from M4Eo. Blood 1991; 78: 451-457.
160. Liu PP, Hajra A, Wijmenga C, Collins FS. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia, (published erratum: Blood 1997; 89: 1842). Blood 1995; 85: 2289-2302.
161. Liu PP, Hajra A, Wijmenga C, Collins FS. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia, (published erratum: Blood 1997; 89: 1842). Blood 1995; 85: 2289-2302.
162. Claxton DF, Liu P, Hsu HB, Marlton P, Hester J, Collins F, Deisseroth AB, Rovvley JD, Siciliano MJ. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994; 83: 1750-1756.
163. Shurtleff SA, Meyers S, Hiebert SW, Raimondi SC, Head DR, Willman CL, Wolman S, Slovak ML, Carroll AJ, Behm F, Hulshof MG, Motroni TA, Okuda T, Liu P, Collins FS, Donning JR. Heterogeneity in CBFbeta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22)in acute myelogenous leukemia. Blood 1995; 85: 3695-3703.
164. Springall FH, Lukeis RF, Tyrrell V, Joshua DE, Hand HJ. Identification of a novel CBFB-MYH11 fusion transcript in a patient with AMF and inversion of chromosome 16. Leukemia 1998; 12: 2034-2035.
165. Van der Reijden BA, Lombardo M, Dauwerse HG, Giles RH, Muhlematter D, Bellomo MJ, Wessels HW, Beverstock GC, van Ommen GJ, Hagemeijer A, Breuning MH. RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts. Blood 1995; 86: 277-282.
166. Kuss BJ, Deeley RG, Cole SP, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Fane SA, Nancarrow JK, Whitmore SA, Callen DF. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion inchromosome 16: prognostic implications. Lancet 1994; 343: 1531-1534.
167. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetic on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
168. Marlton P, Claxton DF, Liu P, Estey EH, Beran M, LeBeau M, Testa JR, Collins FS, Rowley JD, Siciliano MJ. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion lor leukemogenesis. Blood 1995; 85: 772-779.
169. Poirel H, Radford-Weiss I, Rack K, Troussard X, Veil A, Valensi F, Picard F, Guesnu M, Leboeuf D, Melle J, Dreyfus F, Flandrin G, Macintyre E. Detection of the chromosome 16 CBFbeta-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995; 85: 1313-1322.
170. Ritter M, Thiede C, Schakel U, Schmidt M, Alpen B, Pascheberg U, Mohr B, Ehninger G, Neubauer A. Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation. Br J Haematol 1997; 98: 969-972.
171. Costello R, Sainty D. Lecine P, Cusenier A, Mozziconacci MJ, Arnoulet C, Maraninchi D, Gastaut JA, Imbert J, Lafage-Pochitaloff M, Gabert J. Detection of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics. Leukemia 1997; 11: 644-650.
172. Langabeer SE, Walker H, Gale RE, Wheatley K, Burnett AK, Goldstone AH, Linch DC. Frequency of CBFbeta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96: 736-739.
173. Narayanan MN, Geary CG, Harrison CJ, Cinkotai KI, Lewis MJ. Three cases of the myelodysplastic syndrome with pericentric inversion of chromosome 16. Br J Haematol 1993; 85: 217-219.
174. Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Esley E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370-2379.
175. Tobal K, Johnson PR, Saunders MJ, Harrison CJ, Liu Yin JA. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol 1995; 91: 104-108.
176. Costello R, Sainty D, Blaise D, Gastaut IA, Gabert J, Poirel H, BuzynVeil A, Macintyre E. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBFbeta/MYH11-positive acute myeloblaslic leukemia. Blood 1997; 89: 2222-2223.
177. Evans PAS, Short MA, Jack AS, Norfolk DR, Child JA, Shiach CR, Davies F, Tobal K, Yin JAL, Morgan GJ. Detection and quantilation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia 1997; 11: 364-369.
178. Marcucci G, Caligiuri MA, Bloomfield CD. Defining the 'absence' of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood 1997; 90: 5022-5024.
179. Laczika K, Novak M, Hilgarth K, Mitterbauer M, Mitterbauer G, Scheidel-Petrovic A, Scholten C, Thalhammer-Scherrer R, Brugger S, Keil F, Schwarzinger I, Haas OA, Lechner K, Jaeger U. Competitive CBFbeta/MYH11 reverse-transriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. J Clin Oncol 1998; 16: 1519-1525.
180. Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 21: 159-166.
181. Hershfield MS, Kurtzberg J, Harden E, Moore JO, Whang-Peng J, Haynes BF. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2′-deoxycoformycin. Proc Natl Acid Sci USA 1984; 81: 253-257.
182. Begley CG, Aplan PA, Davey MP, Nakahara K, Tchorz K, Kurtzberg J, Hershfield MS, Haynes BF, Cohen DI, Waldmann TA, Kirsch I. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-Cell antigen receptor δ-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci USA 1989; 86: 2031-2035.
183. Brown L, Cheng J-T, Chen Q, Siciliano M, Crist W, Buchanan G, Baer R. Site specific recombination of the TALI gene is a common occurrence in human T-cell leukemia. EMBO J 1990; 9: 3343-3351.
184. Delabesse E, Bernard M, Meyer V, Smit L, Pulford K, Cayuela JM, Ritz J, Bourquelot P, Strominger JL, Valensi F, Macintyre EA. TAL1 expression does not occur in the majority of T-ALL blasts. Br J Haematol 1998; 102: 449-457.
185. Begley CG, Green AR. The SCL gene: from case report to critical hematopoietic regulator. Blood 1999; 93: 2760-2770.
186. Aplan PD, Lombardi DP, Kirsch I. Structural characterization of SIL, a gene frequently disrupted in T-cell acute lymphoblastic leukemia. Mol Cell Biol 1991; 11: 5462-5469.
187. Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J, Carroll AJ, Buchanan GK, Smith RG, Baer R. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study. Blood 1993; 81: 2110-2117.
188. Chen Q, Cheng J-Y, Tsai L-H, Schneider N, Buchanan G, Carroll A, Crist W, Ozanne B, Siciliano M, Baer R. The tal gene undergoes chromosome translocation in a T-cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J 1990; 9: 415-424.
189. Aplan PD, Lombardi DP, Reeman GH, Sather HN, Hammond GD, Kirsch I. Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood 1992; 79: 1327-1333.
190. Delabesse E, Bernard M, Landman-Parker J, Davi F, Leboeuf D, Varel B, Valensi F, Macintyre E. Simultaneous SIL-TAL1 RT-PCR detection of all tald deletions and identification of novel tald variants. Br J Haematol 1997: 99: 901-907.
191. Huang W, Kuang SQ, Huang QH, Dong S, Zhang T. Gu LJ, Ching LM, Chen SJ, Chang LC, Chen Z. RT-PCR detection of SIL-TAL1 fusion mRNA in Chinese T-cell acute lymphoblastic leukemia (T-ALL). Cancer Genet Cytogenet 1995; 81: 76-82.
192. Stock W, Westbrook CA, Sher DA, Dodge R, Sobol RE, Wurster-Hill D, Davey FR, Larson RA, Le Beau MM, Aplan PD, Frankel SR, Stewart CC, Bloomfield CD. Low incidence of TAL1 gene rearrangements in adult acute lymphoblastic leukemia: a cancer and leukemia group B study (8762). Clin Cancer Res 1995; 1: 459-463.
193. Breit TM, Beishuizen A, Ludwig WD, Mol EJ, Adriaansen HJ, Van Wering ER, Van Dongen JJM. TAL1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 1993; 7: 2004-2011.
194. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998; 12: 1482-1489.
195. Pongers-Willemse MJ, Verhagen OJHM, Tibbe GJM, Wijkhuijs AJM, De Haas V, Roovers E, Van der Schoot CE, Van Dongen JJM. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014.
196. Gabert J. Detection of recurrent translocations using real time PCR; assessment of the technique for diagnosis and detection of minimal residual disease. Haematologica 1999; 84: 107-109.